MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.18.00690

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.

Gerson James N, Handorf Elizabeth, Villa Diego, Gerrie Alina S, Chapani Parv, Li Shaoying, Medeiros L Jeffrey, Wang Michael I, Cohen Jonathon B, Calzada Oscar, Churnetski Michael C, Hill Brian T, Sawalha Yazeed, Hernandez-Ilizaliturri Francisco J, Kothari Shalin, Vose Julie M, Bast Martin A, Fenske Timothy S, Narayana Rao Gari Swapna, Maddocks Kami J, Bond David, Bachanova Veronika, Kolla Bhaskar, Chavez Julio, Shah Bijal, Lansigan Frederick, Burns Timothy F, Donovan Alexandra M, Wagner-Johnston Nina, Messmer Marcus, Mehta Amitkumar, Anderson Jennifer K, Reddy Nishitha, Kovach Alexandra E, Landsburg Daniel J, Glenn Martha, Inwards David J, Karmali Reem, Kaplan Jason B, Caimi Paolo F, Rajguru Saurabh, Evens Andrew, Klein Andreas, Umyarova Elvira, Pulluri Bhargavi, Amengual Jennifer E, Lue Jennifer K, Diefenbach Catherine, Fisher Richard I, Barta Stefan K

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

PURPOSE: Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy is often used for eligible patients; however, the benefit remains uncertain in the rituximab era. Herein we retrospectively assessed the impact of AHCT consolidation on survival in a large cohort of transplantation-eligible patients age 65 years or younger.

PATIENTS AND

METHODS

We retrospectively studied transplantation-eligible adults age 65 years or younger with newly diagnosed MCL treated between 2000 and 2015. The primary objective was to assess for improved progression-free survival (PFS) with AHCT consolidation and secondarily to assess for improved overall survival (OS). Cox multivariable regression analysis and propensity score-weighted (PSW) analysis were performed.

RESULTS

Data were collected from 25 medical centers for 1,254 patients; 1,029 met inclusion criteria. Median follow-up for the cohort was 76 months. Median PFS and OS were 62 and 139 months, respectively. On unadjusted analysis, AHCT was associated with improved PFS (75 v 44 months with v without AHCT, respectively; P < .01) and OS (147 v 115 months with v without AHCT, respectively; P < .05). On multivariable regression analysis, AHCT was associated with improved PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66; P < .01) and a trend toward improved OS (HR, 0.77; 95% CI, 0.59 to 1.01; P = .06). After PSW analysis, AHCT remained associated with improved PFS (HR, 0.70; 95% CI, 0.59 to 0.84; P < .05) but not improved OS (HR, 0.87; 95% CI, 0.69 to 1.1; P = .2).

CONCLUSION

In this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our findings suggest that in younger, fit patients, AHCT consolidation may improve PFS.

Для цитирования: Gerson James N, Handorf Elizabeth, Villa Diego, Gerrie Alina S, Chapani Parv, Li Shaoying, Medeiros L Jeffrey, Wang Michael I, Cohen Jonathon B, Calzada Oscar, Churnetski Michael C, Hill Brian T, Sawalha Yazeed, Hernandez-Ilizaliturri Francisco J, Kothari Shalin, Vose Julie M, Bast Martin A, Fenske Timothy S, Narayana Rao Gari Swapna, Maddocks Kami J, Bond David, Bachanova Veronika, Kolla Bhaskar, Chavez Julio, Shah Bijal, Lansigan Frederick, Burns Timothy F, Donovan Alexandra M, Wagner-Johnston Nina, Messmer Marcus, Mehta Amitkumar, Anderson Jennifer K, Reddy Nishitha, Kovach Alexandra E, Landsburg Daniel J, Glenn Martha, Inwards David J, Karmali Reem, Kaplan Jason B, Caimi Paolo F, Rajguru Saurabh, Evens Andrew, Klein Andreas, Umyarova Elvira, Pulluri Bhargavi, Amengual Jennifer E, Lue Jennifer K, Diefenbach Catherine, Fisher Richard I, Barta Stefan K. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019. DOI: 10.1200/jco.18.00690.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.